Dual-targeted drug design of HER2 and HSP90 by CoMFA model and pharmacophore analysis

ASIA unversity > 資訊學院 > 生物資訊與醫學工程學系 > 會議論文 > Item 310904400/8774

請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/8774

題名:	Dual-targeted drug design of HER2 and HSP90 by CoMFA model and pharmacophore analysis
作者:	Huang, Hung-Jin;Bau, Da-Tian;Tsai, Ming-Hsui;Hsu, Yuan-Man;Ho, Tin-Yun;Chen, Chien-Yu;Chang, Yea-Huey;Tsai, Fuu-Jen;Tsai, Chang-Hai;Chen, Calvin Yu-Chian
貢獻者:	Department of Bioinformatics
關鍵詞:	Biomedical engineering;Cell proliferation;Pharmacodynamics;Proteins;Targets;Cancer cells;Cancer therapy;CoMFA;Comparative molecular field analysis;Contour map;Cost differences;Cross validation;Drug Design;Heat shock protein;Human epidermal growth factor;Pharmacophore models;Pharmacophores;Predictive models;Signal pathways
日期:	2009
上傳時間:	2010-04-08 12:05:57 (UTC+0)
出版者:	Asia University
摘要:	Heat shock protein 90 (HSP90) and human epidermal growth factor receptor 2 protein (HER2) are involved in several signal pathways for cancer cell proliferation. We focused on these two hallmarkers to design the dual-targeted inhibitors for cancer therapy. The comparative molecular field analysis (CoMFA) and pharmacophore analysis were employed for generating the predictive models. According the leave-one out (LOO) cross-validation, the CoMFA models obtained the significant r2 values of 0.978 and 0.974 for HSP90 and HER2, respectively. The contour maps of both targets indicated that there were amount of similar bulky favors area. Besides, the cost difference of pharmacophore models was 48.539 for 70% correlation with the experiment. The queries at 3-N and 6-N position of purine-based compound had the similar distributions. This study provided important information for design the HER2 and HSP90 dual-targeted inhibitors ©2009 IEEE.
關聯:	Proceedings of the 2009 2nd International Conference on Biomedical Engineering and Informatics, BMEI 2009
顯示於類別:	[生物資訊與醫學工程學系 ] 會議論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
		0Kb	Unknown	680	檢視/開啟
310904400-8774.doc		47Kb	Microsoft Word	513	檢視/開啟

在ASIAIR中所有的資料項目都受到原著作權保護.

資料載入中.....